Compare · DCTH vs MDLN
DCTH vs MDLN
Side-by-side comparison of Delcath Systems Inc. (DCTH) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCTH and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 79.8x DCTH ($587.1M).
- Over the past year, DCTH is up 51.6% and MDLN is down 12.5% - DCTH leads by 64.2 points.
- MDLN has been more active in the news (12 items in the past 4 weeks vs 6 for DCTH).
- MDLN has more recent analyst coverage (25 ratings vs 4 for DCTH).
- Company
- Delcath Systems Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $587.1M
- $46.86B
- 1M return
- +41.46%
- -10.28%
- 1Y return
- +51.61%
- -12.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 6
- 12
- Recent ratings
- 4
- 25
Delcath Systems Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Latest DCTH
- SEC Form S-8 filed by Delcath Systems Inc.
- SEC Form 8-K filed by Delcath Systems Inc.
- FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC
- SEC Form 10-Q filed by Delcath Systems Inc.
- Delcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Delcath Systems Reports Second Quarter 2026 Results and Business Highlights
- Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference
- Delcath Systems to Host Second Quarter 2026 Earnings Call
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.